Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (31211) 31211
Newsletter (2362) 2362
Book Chapter (438) 438
Newspaper Article (104) 104
Dissertation (76) 76
Magazine Article (70) 70
Publication (49) 49
Book / eBook (18) 18
Reference (9) 9
Conference Proceeding (8) 8
Web Resource (8) 8
Transcript (4) 4
Book Review (3) 3
Streaming Video (2) 2
Data Set (1) 1
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (21325) 21325
life sciences & biomedicine (20640) 20640
humans (18463) 18463
male (12799) 12799
angiotensin (10981) 10981
animals (9682) 9682
female (9095) 9095
cardiovascular system & cardiology (7715) 7715
hypertension (7694) 7694
angiotensin-converting enzyme inhibitors - therapeutic use (6829) 6829
middle aged (6355) 6355
biological and medical sciences (6242) 6242
medical sciences (5632) 5632
aged (5606) 5606
hypertension - drug therapy (5590) 5590
rats (4750) 4750
angiotensin ii type 1 receptor blockers - therapeutic use (4307) 4307
cardiac & cardiovascular systems (4269) 4269
peripheral vascular disease (4182) 4182
blood pressure - drug effects (3914) 3914
angiotensin ii (3878) 3878
antihypertensive agents - therapeutic use (3873) 3873
pharmacology & pharmacy (3735) 3735
research (3649) 3649
adult (3569) 3569
heart failure (3542) 3542
blood pressure (3445) 3445
treatment outcome (3436) 3436
risk factors (3431) 3431
renin-angiotensin system - drug effects (3258) 3258
angiotensin ii type 1 receptor blockers - pharmacology (3218) 3218
renin-angiotensin system (2808) 2808
abridged index medicus (2759) 2759
drug therapy (2693) 2693
hypertension - physiopathology (2579) 2579
enzymes (2569) 2569
drug therapy, combination (2557) 2557
ace inhibitors (2531) 2531
diabetes (2511) 2511
cardiology. vascular system (2439) 2439
analysis (2321) 2321
angiotensin receptor antagonists (2243) 2243
pharmacology. drug treatments (2192) 2192
cardiovascular system (2165) 2165
tetrazoles - therapeutic use (2159) 2159
angiotensin-converting enzyme inhibitors - pharmacology (2145) 2145
urology & nephrology (2140) 2140
heart failure - drug therapy (2128) 2128
care and treatment (2123) 2123
general & internal medicine (2042) 2042
medicine & public health (2033) 2033
adrenergic beta-antagonists - therapeutic use (2009) 2009
mice (1987) 1987
renin-angiotensin system - physiology (1942) 1942
medicine, general & internal (1941) 1941
angiotensin receptor antagonists - therapeutic use (1888) 1888
angiotensin ii - pharmacology (1886) 1886
health aspects (1878) 1878
physiology (1856) 1856
heart (1844) 1844
tetrazoles - pharmacology (1827) 1827
mortality (1787) 1787
rats, sprague-dawley (1762) 1762
time factors (1758) 1758
cardiology (1722) 1722
aged, 80 and over (1657) 1657
hypertension - complications (1625) 1625
enzyme inhibitors (1617) 1617
internal medicine (1586) 1586
losartan - pharmacology (1581) 1581
angiotensin-converting enzyme inhibitors (1560) 1560
antihypertensive agents - pharmacology (1543) 1543
dose-response relationship, drug (1540) 1540
disease models, animal (1534) 1534
physiological aspects (1517) 1517
blood and lymphatic vessels (1512) 1512
calcium channel blockers - therapeutic use (1460) 1460
renin (1457) 1457
medicine (1450) 1450
valsartan (1441) 1441
angiotensin ii - metabolism (1440) 1440
cardiovascular disease (1436) 1436
cardiovascular (1416) 1416
rodents (1401) 1401
medical research (1360) 1360
kidney diseases (1356) 1356
cardiovascular diseases (1352) 1352
angiotensin-converting enzyme inhibitors - adverse effects (1346) 1346
receptor, angiotensin, type 1 - metabolism (1340) 1340
endocrinology & metabolism (1302) 1302
benzimidazoles - therapeutic use (1283) 1283
rats, wistar (1273) 1273
prospective studies (1249) 1249
retrospective studies (1248) 1248
aldosterone (1230) 1230
angiotensin ii type 1 receptor blockers - administration & dosage (1222) 1222
arterial hypertension. arterial hypotension (1222) 1222
losartan (1211) 1211
benzimidazoles - pharmacology (1203) 1203
angiotensin ii receptor blockers (1200) 1200
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (33269) 33269
Japanese (557) 557
German (255) 255
Russian (198) 198
Chinese (154) 154
French (132) 132
Spanish (120) 120
Portuguese (102) 102
Italian (80) 80
Korean (52) 52
Hungarian (37) 37
Polish (31) 31
Czech (27) 27
Danish (22) 22
Dutch (15) 15
Norwegian (15) 15
Swedish (14) 14
Turkish (10) 10
Ukrainian (8) 8
Croatian (6) 6
Finnish (5) 5
Serbian (5) 5
Slovak (5) 5
Hebrew (4) 4
Persian (4) 4
Lithuanian (3) 3
Romanian (2) 2
Bosnian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence?
by Patel, Ankit B and Verma, Ashish
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 03/2020, Volume 323, Issue 18, pp. 1769 - 1770
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Pandemics | Humans | Hypertension - drug therapy | Peptidyl-Dipeptidase A - drug effects | Virus Internalization | COVID-19 | Lung Injury - enzymology | SARS-CoV-2 | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Coronavirus Infections - epidemiology | Pneumonia, Viral - epidemiology | Pneumonia, Viral - complications | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Peptidyl-Dipeptidase A - metabolism | Betacoronavirus | Coronavirus Infections - complications | Lung Injury - drug therapy | Vasodilation - physiology | Antihypertensive Agents - therapeutic use | SARS Virus - pathogenicity | Antihypertensive Agents - adverse effects | Angiotensin-Converting Enzyme 2 | Animals | Hypertension - complications | Mice | Angiotensin Receptor Antagonists - therapeutic use | Angiotensin Receptor Antagonists - adverse effects | Hypertension | Pharmacology, Experimental | Comorbidity | Patient outcomes | Angiotensin II receptor blockers | Specialties and specialists | Practice | Research | Standards | Medicine | Physiology, Pathological | Complications and side effects | Physiological aspects | ACE inhibitors | Angiotensin-converting enzyme inhibitors | Enzymes | Receptors | Enzyme inhibitors | Inhibitors | Converting | Peptidyl-dipeptidase A | Angiotensin | Diuretics | Coronaviruses | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Combined Effect of Angiotensin II Receptor Blocker and Either a Calcium Channel Blocker or Diuretic on Day-by-Day Variability of Home Blood Pressure: The Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study
by Matsui, Yoshio and OʼRourke, Michael F and Hoshide, Satoshi and Ishikawa, Joji and Shimada, Kazuyuki and Kario, Kazuomi
Hypertension (Dallas, Tex. 1979), ISSN 0194-911X, 06/2012, Volume 59, Issue 6, pp. 1132 - 1138
Home blood pressure | Pulse wave velocity | Day-by-day home blood pressure variability | Angiotensin II receptor blocker | Thiazide diuretic | Calcium channel blocker | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Cardiovascular system | Cardiology. Vascular system | Arterial hypertension. Arterial hypotension | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Blood and lymphatic vessels | Antihypertensive agents | Multivariate Analysis | Prospective Studies | Drug Administration Schedule | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Middle Aged | Calcium Channel Blockers - therapeutic use | Hypertension - drug therapy | Male | Treatment Outcome | Azetidinecarboxylic Acid - analogs & derivatives | Hypertension - physiopathology | Dihydropyridines - therapeutic use | Azetidinecarboxylic Acid - therapeutic use | Diuretics - therapeutic use | Female | Tetrazoles - therapeutic use | Aged | Blood Pressure - drug effects | Blood Pressure Monitoring, Ambulatory - methods | Imidazoles - therapeutic use | Drug Therapy, Combination | Hydrochlorothiazide - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Rationale and design of a randomized clinical trial of β-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome
by Lacro, Ronald V., MD and Dietz, Harry C., MD and Wruck, Lisa M., PhD and Bradley, Timothy J., MD and Colan, Steven D., MD and Devereux, Richard B., MD and Klein, Gloria L., MS and Li, Jennifer S., MD and Minich, L. LuAnn, MD and Paridon, Stephen M., MD and Pearson, Gail D., MD, ScD and Printz, Beth F., MD and Pyeritz, Reed E., MD, PhD and Radojewski, Elizabeth, RN and Roman, Mary J., MD and Saul, J. Philip, MD and Stylianou, Mario P., PhD and Mahony, Lynn, MD and for the Pediatric Heart Network Investigators and Pediat Heart Network Investigators and Pediatric Heart Network Investigators
The American heart journal, ISSN 0002-8703, 2007, Volume 154, Issue 4, pp. 624 - 631
Cardiovascular | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Cardiology. Vascular system | Biological and medical sciences | Medical sciences | Atenolol - therapeutic use | Marfan Syndrome - drug therapy | Outcome Assessment (Health Care) | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Humans | Losartan - therapeutic use | Adult | Marfan Syndrome - complications | Research Design | Adrenergic beta-Antagonists - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
by Danser, A.H Jan and Epstein, Murray and Batlle, Daniel
Hypertension (Dallas, Tex. 1979), ISSN 0194-911X, 06/2020, Volume 75, Issue 6, pp. 1382 - 1385
COVID-19 | coronavirus | angiotensin receptor blocker | ACE inhibitor | severe acute respiratory syndrome | Pandemics | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Coronavirus Infections - drug therapy | Humans | Pneumonia, Viral - drug therapy | Coronavirus Infections - physiopathology | Peptidyl-Dipeptidase A - physiology | Renin-Angiotensin System - physiology | Angiotensin II Type 1 Receptor Blockers - pharmacology | Pneumonia, Viral - physiopathology | Receptors, Virus - physiology | Pneumonia, Viral - metabolism | Animals | Coronavirus Infections - metabolism | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Betacoronavirus | Renin-Angiotensin System - drug effects | Angiotensin-Converting Enzyme Inhibitors - pharmacology | Receptors, Virus - antagonists & inhibitors | Index Medicus | Reviews | 10010 | 10111
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Effects of Angiotensin II Receptor Blockers and ACE (Angiotensin-Converting Enzyme) Inhibitors on Virus Infection, Inflammatory Status, and Clinical Outcomes in Patients With COVID-19 and Hypertension: A Single-Center Retrospective Study
by Yang, Guang and Tan, Zihu and Zhou, Ling and Yang, Min and Peng, Lang and Liu, Jinjin and Cai, Jingling and Yang, Ru and Han, Junyan and Huang, Yafei and He, Shaobin
Hypertension (Dallas, Tex. 1979), ISSN 0194-911X, 07/2020, Volume 76, Issue 1, pp. 51 - 58
COVID-19 | coronavirus | angiotensin-converting enzyme inhibitors | angiotensin receptor blocker | inflammation | hypertension | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Pandemics | Humans | Middle Aged | Medication Therapy Management - statistics & numerical data | Hypertension - drug therapy | Male | Procalcitonin - analysis | Hypertension - blood | SARS-CoV-2 | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Coronavirus Infections - epidemiology | Pneumonia, Viral - epidemiology | Peptidyl-Dipeptidase A - metabolism | Female | Retrospective Studies | Hypertension - epidemiology | C-Reactive Protein - analysis | Betacoronavirus - isolation & purification | Comorbidity | Pneumonia, Viral - therapy | Treatment Outcome | China - epidemiology | Coronavirus Infections - immunology | Pneumonia, Viral - immunology | Angiotensin-Converting Enzyme 2 | Coronavirus Infections - therapy | Hypertension - virology | Survival Analysis | Aged | Angiotensin Receptor Antagonists - therapeutic use | Virus diseases | Hypertension | Care and treatment | Patient outcomes | Severe acute respiratory syndrome | Angiotensin | Antihypertensive drugs | Epidemiology | ACE inhibitors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Age-Related Difference in the Sleep Pressure-Lowering Effect Between an Angiotensin II Receptor Blocker and a Calcium Channel Blocker in Asian Hypertensives: The ACS1 Study
by Kario, Kazuomi and Hoshide, Satoshi
Hypertension (Dallas, Tex. 1979), ISSN 0194-911X, 04/2015, Volume 65, Issue 4, pp. 729 - 735
ambulatory blood pressure monitoring | control rate | hypertension | amlodipine | azilsartan | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Japan - epidemiology | Oxadiazoles - administration & dosage | Administration, Oral | Humans | Middle Aged | Hypertension - drug therapy | Male | Treatment Outcome | Sleep - drug effects | Hypertension - physiopathology | Incidence | Dose-Response Relationship, Drug | Benzimidazoles - administration & dosage | Calcium Channel Blockers - administration & dosage | Female | Aged | Blood Pressure - drug effects | Blood Pressure - physiology | Hypertension - epidemiology | Blood Pressure Monitoring, Ambulatory | Amlodipine - administration & dosage | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Angiotensin receptor blockers and COVID-19
by Saavedra, Juan M
Pharmacological research, ISSN 1043-6618, 06/2020, Volume 156, pp. 104832 - 104832
COVID-19 | ACE2 | SARS-CoV-2 | Coronavirus | Angiotensin receptor blockers | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Hypertension | Coronavirus Infections | Pandemics | Angiotensin Receptor Antagonists | Humans | Betacoronavirus | Pneumonia, Viral | Peptidyl-Dipeptidase A | Diabetes Mellitus | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis - A randomized study
by Takahashi, Akihiko and Takase, Hiroyuki and Toriyama, Takayuki and Sugiura, Tomonori and Kurita, Yutaka and Ueda, Ryuzo and Dohi, Yasuaki
Nephrology, dialysis, transplantation, ISSN 0931-0509, 09/2006, Volume 21, Issue 9, pp. 2507 - 2512
Brain natriuretic peptide | Cardiovascular disease | Angiotensin receptor antagonists | Randomized trail | Congestive heart failure | Cardiovascular mortality | Transplantation | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Diabetes. Impaired glucose tolerance | Emergency and intensive care: renal failure. Dialysis management | Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy | Nephropathies. Renovascular diseases. Renal failure | Renal failure | Nephrology. Urinary tract diseases | Biological and medical sciences | Endocrinopathies | Intensive care medicine | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Associated diseases and complications | Cardiovascular Diseases - etiology | Japan - epidemiology | Prospective Studies | Follow-Up Studies | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Proportional Hazards Models | Male | Survival Rate | Treatment Outcome | Incidence | Kidney Failure, Chronic - therapy | Renal Dialysis - adverse effects | Cardiovascular Diseases - epidemiology | Female | Tetrazoles - therapeutic use | Benzimidazoles - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial
by Sandset, Else Charlotte, MD and Bath, Philip MW, Prof and Boysen, Gudrun, Prof and Jatuzis, Dalius, MD and Kõrv, Janika, MD and Lüders, Stephan, MD and Murray, Gordon D, Prof and Richter, Przemyslaw S, MD and Roine, Risto O, Prof and Terént, Andreas, Prof and Thijs, Vincent, MD and Berge, Eivind, Dr and on behalf of the SCAST Study Group and SCAST Study Grp and SCAST Study Group
The Lancet (British edition), ISSN 0140-6736, 2011, Volume 377, Issue 9767, pp. 741 - 750
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Neurology | Biological and medical sciences | General aspects | Vascular diseases and vascular malformations of the nervous system | Medical sciences | Meta-Analysis as Topic | Angiotensin II Type 1 Receptor Blockers - adverse effects | Humans | Middle Aged | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Stroke - physiopathology | Benzimidazoles - administration & dosage | Tetrazoles - administration & dosage | Treatment Failure | Aged, 80 and over | Female | Blood Pressure - drug effects | Benzimidazoles - adverse effects | Odds Ratio | Angiotensin II Type 1 Receptor Blockers - administration & dosage | Brain Ischemia - complications | Double-Blind Method | Drug Administration Schedule | Europe | Stroke - drug therapy | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | Regression Analysis | Stroke - etiology | Aged | Tetrazoles - adverse effects | Cerebral Hemorrhage - complications | Hypertension | Stroke (Disease) | Complications and side effects | Candesartan | Research | Drug therapy | Health aspects | Studies | Stroke | Blood pressure | Clinical medicine | Index Medicus | Abridged Index Medicus | blood pressure | Hospitals | stroke | Mortality | myocardial infarction | composite materials | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE Inhibitor and Ang II (Angiotensin II) Receptor Blocker Use During the Pandemic: The Pediatric Perspective
by South, Andrew M and Brady, Tammy M and Flynn, Joseph T
Hypertension (Dallas, Tex. 1979), ISSN 0194-911X, 07/2020, Volume 76, Issue 1, pp. 16 - 22
Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Pandemics | Comorbidity | Humans | Angiotensin Receptor Antagonists - pharmacology | Hypertension - drug therapy | Renin-Angiotensin System - physiology | Hypertension - metabolism | COVID-19 | Pneumonia, Viral - metabolism | Angiotensin-Converting Enzyme 2 | SARS-CoV-2 | Coronavirus Infections - metabolism | Coronavirus Infections - epidemiology | Coronavirus Infections - virology | Pneumonia, Viral - epidemiology | Betacoronavirus - physiology | Peptidyl-Dipeptidase A - metabolism | Renin-Angiotensin System - drug effects | Angiotensin-Converting Enzyme Inhibitors - pharmacology | Hypertension - epidemiology | Child | Pneumonia, Viral - virology | Hypertension | Pediatrics | Medical colleges | Angiotensin | Kidney diseases | Children | Coronaviruses | Epidemiology | ACE inhibitors | Risk factors | Diseases | Cardiovascular agents | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19
by Zhang, Peng and Zhu, Lihua and Cai, Jingjing and Lei, Fang and Qin, Juan-Juan and Xie, Jing and Liu, Ye-Mao and Zhao, Yan-Ci and Huang, Xuewei and Lin, Lijin and Xia, Meng and Chen, Ming-Ming and Cheng, Xu and Zhang, Xiao and Guo, Deliang and Peng, Yuanyuan and Ji, Yan-Xiao and Chen, Jing and She, Zhi-Gang and Wang, Yibin and Xu, Qingbo and Tan, Renfu and Wang, Haitao and Lin, Jun and Luo, Pengcheng and Fu, Shouzhi and Cai, Hongbin and Ye, Ping and Xiao, Bing and Mao, Weiming and Liu, Liming and Yan, Youqin and Liu, Mingyu and Chen, Manhua and Zhang, Xiao-Jing and Wang, Xinghuan and Touyz, Rhian M and Xia, Jiahong and Zhang, Bing-Hong and Huang, Xiaodong and Yuan, Yufeng and Rohit, Loomba and Liu, Peter P and Li, Hongliang
Circulation research, ISSN 0009-7330, 06/2020, Volume 126, Issue 12, pp. 1671 - 1681
Cardiac & Cardiovascular Systems | Peripheral Vascular Disease | Life Sciences & Biomedicine | Hematology | Cardiovascular System & Cardiology | Science & Technology | Pandemics | Hospital Mortality | Humans | Middle Aged | Hypertension - drug therapy | Male | Inpatients - statistics & numerical data | COVID-19 | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Coronavirus Infections - epidemiology | Pneumonia, Viral - epidemiology | Pneumonia, Viral - complications | Angiotensin-Converting Enzyme Inhibitors - adverse effects | Coronavirus Infections - complications | Hypertension - complications | Female | Aged | Hypertension - epidemiology | Angiotensin Receptor Antagonists - therapeutic use | Angiotensin Receptor Antagonists - adverse effects | Hypertension | Medical research | Patient outcomes | Analysis | Mortality | Angiotensin | Medicine, Experimental | Antihypertensive drugs | Coronaviruses | ACE inhibitors | Index Medicus | inpatients | Original Research | angiotensin-converting enzyme inhibitor | angiotensin II receptor blocker | 10010 | coronavirus | hypertension
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights